CINCINNATI--(BUSINESS WIRE)--Meridian Life Science, Inc., (MLS) of Memphis, Tennessee, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), recently completed the manufacture of a human rhinovirus Type 16 challenge stock. MLS manufactured the rhinovirus challenge stock under contract and according to the appropriate current Good Manufacturing Procedures (cGMPs) for use in early-phase human clinical trials while simultaneously meeting the desired titer specifications under aggressive timelines.
